Jobs
View more job listings or post a job
Alturas Analytics Scientist 1
University of California, Davis TOXICOLOGY ANALYTICAL CHEMIST (STAFF RESEARCH ASSOCIATE 3)
University of California, Davis CALIFORNIA ANIMAL HEALTH AND FOOD SAFETY LABORATORY - TOXICOLOGY LAB RESEARCH SUPERVISOR/GROUP LEADER
Eli Lilly and Company R-39973 Scientific Director ADME - Novel Modalities (Open)
FibroGen Director DMPK
Applied BioMath Technical Marketing Specialist
Horizon Therapeutics Director, Bioanalytical Sciences
Exelixis Principal Scientist - DMPK
Exelixis Senior Principal Scientist - DMPK
Exelixis Principal Clinical DMPK Scientist
Post a job

Symposium

PBSS-SOT Joint Symposium: Combination Therapy Drug Development: Fundamentals, Advances, and Case Studies


Speakers: Joseph Francisco (CRL), Philip Gatti (FDA), Paul Feldman (Intarcia), Jonathan Wang (Genentech), Lynn Genarro (Genentech), Rosa Chan (UCSF), Anne Chester (Gilead), Rebecca Begley (Gilead), Jessica Hawes (FDA)
Organizers:
Date: 2017-05-16
Time: 7:30-17:30 Pacific Time
Registration fee: (USD): Regular: $50; Academic: $50; Students or Unemployed: $50
Location: South San Francisco Conference Center (255 South Airport Boulevard, South San Francisco, CA 94080)
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2017-05-15  (it will close sooner if the seating cap is reached)

About the Topic

Morning Session

7:30 am – 8:30 am       Registration & Breakfast

8:30 am – 8:45 am       Opening message from The NorCal & PBSS Presidents (Toufan Parman, PhD, DABT, Director, General Toxicology, SRI; Shichang Miao, PhD, VP, Preclinical Development & Clinical DMPK, ChemoCentryx)

8:45 am – 9:20 am       Introduction to the Preclinical Development of Combination Therapies (Joseph Francisco, CRL)

9:20 am – 9:55 am       Safety Assessment of Combination Therapeutic Agents: Regulatory Guidance and Expectations (Philip Gatti, FDA)

9:55 am – 10:30 am     Addressing The Challenges With The Discovery of Combination Peptide (Paul Feldman, Intarcia)

10:30 am – 10:45 am   Coffee Break

10:45 am – 10:55 am   Sponsor Platform AM: TBD

10:55 am – 11:30 am   Challenges and solutions in the development of multi-analyte bioanalytical methods (Jonathan Wang, Genentech)

11:30 am – 12:05 am   Presentation 4: TBD (Lynn Genarro, Genentech)

12:05 pm – 1:30 pm    Lunch Break: Lunch with Experts, Posters

Afternoon Session

1:30 pm – 1:45 pm      Chapter announcements and acknowledgements

1:45 am – 2:05 am       NorCal Student Award presentation: Evaluation of DILI Predictive Hypotheses in Early Drug Development (Rosa Chan, UCSF)

2:05 pm – 2:40 pm      Combination Toxicity Study of 2 Approved Cardiovascular Drugs (Anne Chester, Gilead)

2:40 pm – 3:00 pm      Coffee Break

3:00 pm – 3:10 pm      Sponsor Platform PM: TBD

3:10 pm – 3:45 pm      Clinical Pharmacology considerations for development of combination products (Rebecca Begley, Gilead)

3:45 pm – 4:20 pm      Combination Drug Applications: Nonclinical Reviewer Perspectives (Jessica Hawes, FDA)

4:20 pm – 4:35 pm      Closing Remarks

4:35 pm – 5:50 pm      Reception & Networking


2023-12-06, [Free Online] Artificial Intelligence and Machine Learning to Drive Therapeutic Drug Discovery & Development
2024-01-19, [In-Person] ADME/DMPK Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-02-06, [In-Person] Antibody Discovery and Development: Hit Generation, Engineering, Characterization, CMC and IND Enabling studies
2024-03-07, [In-Person] Project Management for Drug Development
2024-03-28, [In-Person] Antibody-Drug Conjugates from Discovery to Development: Chemistry, Engineering, Characterization, CMC, PK/Tox, Clinical design and Intellectual Property
┬ęPharmaceutical & BioScience Society, International; Last Modified: 12/5/2023; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

ICON Innovation Workshop in SF Bay Area: Bringing the trial to the patient: Are you driving true patient centricity? Oct 19, Crowne Plaza Foster
Viva Biotech Join Viva Reception if you have a need in MedChem, SBDD, FBDD, CryoEM, ASMS, SPR, HDX, CADD, Bioassay, CMC, Ab, https://www.bagevent.com/event/8673557
BioTether Sciences Bioanalytical CRO, focused on PK, Biomarkers, and Immunogenicity. Custom Assay development, validation and testing. Advanced cell engineering.
Allucent Bringing innovation to Biopharma, w/ClinPharm Modeling & Simulation services to inform dose, design, modeling + development strategies.
Hypha Discovery Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
Alturas Analytics, Inc. Expert GLP & non-GLP LC-MS/MS, GC-MS/MS bioanalytical & PK/TK analysis services of small & large molecules in any matrix. Discovery through phase IV.
Submit a Text Ad